Do analysts recommend CRVL or BTSG?

BrightSpring Health Services has a consensus price target of $70.71, indicating a potential upside of 18.77%. Given BrightSpring Health Services' stronger consensus rating and higher possible upside, analysts clearly believe BrightSpring Health Services is more favorable than CorVel. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CorVel 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 BrightSpring Health Services 0 Sell rating(s) 0 Hold rating(s) 18 Buy rating(s) 2 Strong Buy rating(s) 3.10

Does the media favor CRVL or BTSG?

In the previous week, BrightSpring Health Services had 7 more articles in the media than CorVel. MarketBeat recorded 9 mentions for BrightSpring Health Services and 2 mentions for CorVel. CorVel's average media sentiment score of 1.73 beat BrightSpring Health Services' score of 1.08 indicating that CorVel is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CorVel 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive BrightSpring Health Services 6 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend CRVL or DVA?

DaVita has a consensus price target of $221.75, suggesting a potential upside of 26.32%. Given DaVita's stronger consensus rating and higher probable upside, analysts plainly believe DaVita is more favorable than CorVel. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CorVel 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 DaVita 1 Sell rating(s) 3 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.38

Which has better valuation and earnings, CRVL or DVA?

DaVita has higher revenue and earnings than CorVel. DaVita is trading at a lower price-to-earnings ratio than CorVel, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CorVel $958.53M 3.74 $110.34M $2.25 31.20 DaVita $13.64B 0.82 $746.80M $12.22 14.36

Is CRVL or DVA more profitable?

CorVel has a net margin of 11.72% compared to DaVita's net margin of 6.05%. CorVel's return on equity of 29.92% beat DaVita's return on equity. Company Net Margins Return on Equity Return on Assets CorVel 11.72% 29.92% 17.82% DaVita 6.05% -217.63% 5.07%

Does the media favor CRVL or DVA?

In the previous week, CorVel had 1 more articles in the media than DaVita. MarketBeat recorded 2 mentions for CorVel and 1 mentions for DaVita. CorVel's average media sentiment score of 1.73 beat DaVita's score of 1.47 indicating that CorVel is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CorVel 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive DaVita 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate TEM or CRVL?

Tempus AI currently has a consensus target price of $65.69, indicating a potential downside of 1.44%. Given Tempus AI's stronger consensus rating and higher possible upside, analysts plainly believe Tempus AI is more favorable than CorVel. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tempus AI 2 Sell rating(s) 6 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.41 CorVel 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has higher earnings & valuation, TEM or CRVL?

CorVel has lower revenue, but higher earnings than Tempus AI. Tempus AI is trading at a lower price-to-earnings ratio than CorVel, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Tempus AI $1.27B 9.46 -$245.03M -$1.44 N/A CorVel $958.53M 3.74 $110.34M $2.25 31.20

Is TEM or CRVL more profitable?

CorVel has a net margin of 11.72% compared to Tempus AI's net margin of -17.77%. CorVel's return on equity of 29.92% beat Tempus AI's return on equity. Company Net Margins Return on Equity Return on Assets Tempus AI -17.77% -50.28% -10.33% CorVel 11.72% 29.92% 17.82%

Does the media refer more to TEM or CRVL?

In the previous week, Tempus AI had 11 more articles in the media than CorVel. MarketBeat recorded 13 mentions for Tempus AI and 2 mentions for CorVel. CorVel's average media sentiment score of 1.73 beat Tempus AI's score of 1.06 indicating that CorVel is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tempus AI 9 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CorVel 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Do analysts prefer CHE or CRVL?

Chemed currently has a consensus price target of $530.75, indicating a potential downside of 0.78%. Given Chemed's stronger consensus rating and higher possible upside, equities research analysts clearly believe Chemed is more favorable than CorVel. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Chemed 0 Sell rating(s) 5 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.17 CorVel 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has higher valuation and earnings, CHE or CRVL?

Chemed has higher revenue and earnings than CorVel. Chemed is trading at a lower price-to-earnings ratio than CorVel, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Chemed $2.53B 2.76 $265.24M $19.91 26.87 CorVel $958.53M 3.74 $110.34M $2.25 31.20

Is CHE or CRVL more profitable?

CorVel has a net margin of 11.72% compared to Chemed's net margin of 10.60%. Chemed's return on equity of 31.77% beat CorVel's return on equity. Company Net Margins Return on Equity Return on Assets Chemed 10.60% 31.77% 18.90% CorVel 11.72% 29.92% 17.82%

Does the media favor CHE or CRVL?

In the previous week, Chemed had 2 more articles in the media than CorVel. MarketBeat recorded 4 mentions for Chemed and 2 mentions for CorVel. Chemed's average media sentiment score of 1.81 beat CorVel's score of 1.73 indicating that Chemed is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Chemed 3 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive CorVel 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Do analysts prefer CRVL or HIMS?

Hims & Hers Health has a consensus price target of $32.43, suggesting a potential upside of 1.51%. Given Hims & Hers Health's stronger consensus rating and higher probable upside, analysts clearly believe Hims & Hers Health is more favorable than CorVel. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CorVel 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Hims & Hers Health 1 Sell rating(s) 11 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.19

Which has stronger earnings and valuation, CRVL or HIMS?

Hims & Hers Health has higher revenue and earnings than CorVel. Hims & Hers Health is trading at a lower price-to-earnings ratio than CorVel, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CorVel $958.53M 3.74 $110.34M $2.25 31.20 Hims & Hers Health $2.35B 3.18 $128.37M -$0.63 N/A

Is CRVL or HIMS more profitable?

CorVel has a net margin of 11.72% compared to Hims & Hers Health's net margin of -5.51%. CorVel's return on equity of 29.92% beat Hims & Hers Health's return on equity. Company Net Margins Return on Equity Return on Assets CorVel 11.72% 29.92% 17.82% Hims & Hers Health -5.51% -6.51% -1.20%

Does the media prefer CRVL or HIMS?

In the previous week, Hims & Hers Health had 33 more articles in the media than CorVel. MarketBeat recorded 35 mentions for Hims & Hers Health and 2 mentions for CorVel. CorVel's average media sentiment score of 1.73 beat Hims & Hers Health's score of 0.21 indicating that CorVel is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CorVel 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Hims & Hers Health 11 Very Positive mention(s) 4 Positive mention(s) 12 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral

CorVel (CRVL) Competitors

$70.21 -0.57 (-0.81%)

Closing price 04:00 PM Eastern

Extended Trading

$70.24 +0.03 (+0.04%)

As of 04:43 PM Eastern

Compare

CRVL vs. BTSG, DVA, TEM, CHE, and HIMS

Should you buy CorVel stock or one of its competitors? CorVel's main competitors and comparable companies include BrightSpring Health Services (BTSG), DaVita (DVA), Tempus AI (TEM), Chemed (CHE), and Hims & Hers Health (HIMS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare services" industry.

How does CorVel compare to BrightSpring Health Services?

CorVel (NASDAQ:CRVL) and BrightSpring Health Services (NASDAQ:BTSG) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, media sentiment, institutional ownership, risk, profitability, analyst recommendations and dividends.

CorVel has a beta of 0.98, meaning that its share price is 2% less volatile than the broader market. Comparatively, BrightSpring Health Services has a beta of 1.88, meaning that its share price is 88% more volatile than the broader market.

51.4% of CorVel shares are owned by institutional investors. 39.7% of CorVel shares are owned by insiders. Comparatively, 2.8% of BrightSpring Health Services shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

CorVel has a net margin of 11.72% compared to BrightSpring Health Services' net margin of 2.55%. CorVel's return on equity of 29.92% beat BrightSpring Health Services' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CorVel	11.72%	29.92%	17.82%
BrightSpring Health Services	2.55%	16.73%	5.24%

BrightSpring Health Services has a consensus price target of $70.71, indicating a potential upside of 18.77%. Given BrightSpring Health Services' stronger consensus rating and higher possible upside, analysts clearly believe BrightSpring Health Services is more favorable than CorVel.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CorVel	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
BrightSpring Health Services	0 Sell rating(s)	0 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	3.10

In the previous week, BrightSpring Health Services had 7 more articles in the media than CorVel. MarketBeat recorded 9 mentions for BrightSpring Health Services and 2 mentions for CorVel. CorVel's average media sentiment score of 1.73 beat BrightSpring Health Services' score of 1.08 indicating that CorVel is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CorVel	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
BrightSpring Health Services	6 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

BrightSpring Health Services has higher revenue and earnings than CorVel. CorVel is trading at a lower price-to-earnings ratio than BrightSpring Health Services, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CorVel	$958.53M	3.74	$110.34M	$2.25	31.20
BrightSpring Health Services	$12.91B	0.91	$190.67M	$1.66	35.86

Summary

BrightSpring Health Services beats CorVel on 9 of the 17 factors compared between the two stocks.

How does CorVel compare to DaVita?

CorVel (NASDAQ:CRVL) and DaVita (NYSE:DVA) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, valuation, media sentiment, analyst recommendations, profitability, dividends, institutional ownership and risk.

DaVita has a consensus price target of $221.75, suggesting a potential upside of 26.32%. Given DaVita's stronger consensus rating and higher probable upside, analysts plainly believe DaVita is more favorable than CorVel.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CorVel	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
DaVita	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.38

DaVita has higher revenue and earnings than CorVel. DaVita is trading at a lower price-to-earnings ratio than CorVel, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CorVel	$958.53M	3.74	$110.34M	$2.25	31.20
DaVita	$13.64B	0.82	$746.80M	$12.22	14.36

CorVel has a beta of 0.98, suggesting that its stock price is 2% less volatile than the broader market. Comparatively, DaVita has a beta of 0.88, suggesting that its stock price is 12% less volatile than the broader market.

51.4% of CorVel shares are held by institutional investors. Comparatively, 90.1% of DaVita shares are held by institutional investors. 39.7% of CorVel shares are held by insiders. Comparatively, 1.9% of DaVita shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

CorVel has a net margin of 11.72% compared to DaVita's net margin of 6.05%. CorVel's return on equity of 29.92% beat DaVita's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CorVel	11.72%	29.92%	17.82%
DaVita	6.05%	-217.63%	5.07%

In the previous week, CorVel had 1 more articles in the media than DaVita. MarketBeat recorded 2 mentions for CorVel and 1 mentions for DaVita. CorVel's average media sentiment score of 1.73 beat DaVita's score of 1.47 indicating that CorVel is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CorVel	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
DaVita	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

CorVel beats DaVita on 9 of the 16 factors compared between the two stocks.

How does CorVel compare to Tempus AI?

Tempus AI (NASDAQ:TEM) and CorVel (NASDAQ:CRVL) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, profitability, risk, earnings, dividends and media sentiment.

Tempus AI has a beta of 3.58, indicating that its stock price is 258% more volatile than the broader market. Comparatively, CorVel has a beta of 0.98, indicating that its stock price is 2% less volatile than the broader market.

24.2% of Tempus AI shares are owned by institutional investors. Comparatively, 51.4% of CorVel shares are owned by institutional investors. 24.3% of Tempus AI shares are owned by insiders. Comparatively, 39.7% of CorVel shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Tempus AI currently has a consensus target price of $65.69, indicating a potential downside of 1.44%. Given Tempus AI's stronger consensus rating and higher possible upside, analysts plainly believe Tempus AI is more favorable than CorVel.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tempus AI	2 Sell rating(s)	6 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.41
CorVel	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Tempus AI had 11 more articles in the media than CorVel. MarketBeat recorded 13 mentions for Tempus AI and 2 mentions for CorVel. CorVel's average media sentiment score of 1.73 beat Tempus AI's score of 1.06 indicating that CorVel is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tempus AI	9 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CorVel	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

CorVel has lower revenue, but higher earnings than Tempus AI. Tempus AI is trading at a lower price-to-earnings ratio than CorVel, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tempus AI	$1.27B	9.46	-$245.03M	-$1.44	N/A
CorVel	$958.53M	3.74	$110.34M	$2.25	31.20

CorVel has a net margin of 11.72% compared to Tempus AI's net margin of -17.77%. CorVel's return on equity of 29.92% beat Tempus AI's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tempus AI	-17.77%	-50.28%	-10.33%
CorVel	11.72%	29.92%	17.82%

Summary

CorVel beats Tempus AI on 9 of the 16 factors compared between the two stocks.

How does CorVel compare to Chemed?

Chemed (NYSE:CHE) and CorVel (NASDAQ:CRVL) are both mid-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, earnings, institutional ownership, profitability, analyst recommendations, dividends and media sentiment.

Chemed has a beta of 0.51, indicating that its share price is 49% less volatile than the broader market. Comparatively, CorVel has a beta of 0.98, indicating that its share price is 2% less volatile than the broader market.

CorVel has a net margin of 11.72% compared to Chemed's net margin of 10.60%. Chemed's return on equity of 31.77% beat CorVel's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Chemed	10.60%	31.77%	18.90%
CorVel	11.72%	29.92%	17.82%

Chemed currently has a consensus price target of $530.75, indicating a potential downside of 0.78%. Given Chemed's stronger consensus rating and higher possible upside, equities research analysts clearly believe Chemed is more favorable than CorVel.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Chemed	0 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.17
CorVel	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

95.9% of Chemed shares are owned by institutional investors. Comparatively, 51.4% of CorVel shares are owned by institutional investors. 3.3% of Chemed shares are owned by company insiders. Comparatively, 39.7% of CorVel shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Chemed had 2 more articles in the media than CorVel. MarketBeat recorded 4 mentions for Chemed and 2 mentions for CorVel. Chemed's average media sentiment score of 1.81 beat CorVel's score of 1.73 indicating that Chemed is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Chemed	3 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
CorVel	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Chemed has higher revenue and earnings than CorVel. Chemed is trading at a lower price-to-earnings ratio than CorVel, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Chemed	$2.53B	2.76	$265.24M	$19.91	26.87
CorVel	$958.53M	3.74	$110.34M	$2.25	31.20

Summary

Chemed beats CorVel on 11 of the 16 factors compared between the two stocks.

How does CorVel compare to Hims & Hers Health?

CorVel (NASDAQ:CRVL) and Hims & Hers Health (NYSE:HIMS) are both mid-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, dividends, valuation, profitability, media sentiment and analyst recommendations.

CorVel has a net margin of 11.72% compared to Hims & Hers Health's net margin of -5.51%. CorVel's return on equity of 29.92% beat Hims & Hers Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CorVel	11.72%	29.92%	17.82%
Hims & Hers Health	-5.51%	-6.51%	-1.20%

Hims & Hers Health has a consensus price target of $32.43, suggesting a potential upside of 1.51%. Given Hims & Hers Health's stronger consensus rating and higher probable upside, analysts clearly believe Hims & Hers Health is more favorable than CorVel.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CorVel	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Hims & Hers Health	1 Sell rating(s)	11 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.19

CorVel has a beta of 0.98, indicating that its stock price is 2% less volatile than the broader market. Comparatively, Hims & Hers Health has a beta of 2.4, indicating that its stock price is 140% more volatile than the broader market.

In the previous week, Hims & Hers Health had 33 more articles in the media than CorVel. MarketBeat recorded 35 mentions for Hims & Hers Health and 2 mentions for CorVel. CorVel's average media sentiment score of 1.73 beat Hims & Hers Health's score of 0.21 indicating that CorVel is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CorVel	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Hims & Hers Health	11 Very Positive mention(s)	4 Positive mention(s)	12 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral

51.4% of CorVel shares are held by institutional investors. Comparatively, 63.5% of Hims & Hers Health shares are held by institutional investors. 39.7% of CorVel shares are held by insiders. Comparatively, 11.8% of Hims & Hers Health shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Hims & Hers Health has higher revenue and earnings than CorVel. Hims & Hers Health is trading at a lower price-to-earnings ratio than CorVel, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CorVel	$958.53M	3.74	$110.34M	$2.25	31.20
Hims & Hers Health	$2.35B	3.18	$128.37M	-$0.63	N/A

Summary

CorVel and Hims & Hers Health tied by winning 8 of the 16 factors compared between the two stocks.

Get CorVel News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CRVL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CRVL vs. The Competition

Export

Metric	CorVel	Healthcare Providers & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$3.58B	$9.71B	$7.22B	$12.76B
Dividend Yield	N/A	2.54%	2.55%	10.29%
P/E Ratio	31.20	34.25	269.18	24.05
Price / Sales	3.74	4.95	621.56	97.96
Price / Cash	24.24	126.93	78.23	52.73
Price / Book	8.75	3.96	13.06	6.16
Net Income	$110.34M	$311.06M	$3.46B	$347.49M
7 Day Performance	8.99%	-0.27%	1.43%	-0.64%
1 Month Performance	14.46%	0.22%	4.58%	2.12%
1 Year Performance	-21.05%	16.66%	27.60%	20.16%

CorVel Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CRVL CorVel	1.4138 of 5 stars	$70.21 -0.8%	N/A	-20.9%	$3.58B	$958.53M	31.20	5,239	Positive News
BTSG BrightSpring Health Services	4.9579 of 5 stars	$58.47 -4.8%	$70.71 +20.9%	+156.0%	$11.56B	$12.91B	35.19	23,500
DVA DaVita	4.8483 of 5 stars	$179.90 -2.1%	$221.75 +23.3%	+29.9%	$11.48B	$13.64B	14.72	78,000	Positive News
TEM Tempus AI	1.7658 of 5 stars	$54.70 -0.7%	$64.92 +18.7%	-16.2%	$9.86B	$1.27B	N/A	3,800	Trending News Analyst Forecast Options Volume
CHE Chemed	4.0795 of 5 stars	$543.35 -1.1%	$530.75 -2.3%	+17.9%	$7.10B	$2.53B	27.29	15,811	Positive News Ex-Dividend

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CRVL) was last updated on 8/20/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

CorVel (CRVL) Competitors

CRVL vs. BTSG, DVA, TEM, CHE, and HIMS

How does CorVel compare to BrightSpring Health Services?

Summary

How does CorVel compare to DaVita?

Summary

How does CorVel compare to Tempus AI?

Summary

How does CorVel compare to Chemed?

Summary

How does CorVel compare to Hims & Hers Health?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRVL vs. The Competition

CorVel Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

CorVel (CRVL) Competitors

CRVL vs. BTSG, DVA, TEM, CHE, and HIMS

How does CorVel compare to BrightSpring Health Services?

Which has more volatility and risk, CRVL or BTSG?

Do insiders & institutionals believe in CRVL or BTSG?

Is CRVL or BTSG more profitable?

Do analysts recommend CRVL or BTSG?

Does the media favor CRVL or BTSG?

Which has higher valuation & earnings, CRVL or BTSG?

Summary

How does CorVel compare to DaVita?

Do analysts recommend CRVL or DVA?

Which has better valuation and earnings, CRVL or DVA?

Which has more volatility & risk, CRVL or DVA?

Do insiders and institutionals hold more shares of CRVL or DVA?

Is CRVL or DVA more profitable?

Does the media favor CRVL or DVA?

Summary

How does CorVel compare to Tempus AI?

Which has more volatility and risk, TEM or CRVL?

Do institutionals & insiders have more ownership in TEM or CRVL?

Do analysts rate TEM or CRVL?

Does the media refer more to TEM or CRVL?

Which has higher earnings & valuation, TEM or CRVL?

Is TEM or CRVL more profitable?

Summary

How does CorVel compare to Chemed?

Which has more risk and volatility, CHE or CRVL?

Is CHE or CRVL more profitable?

Do analysts prefer CHE or CRVL?

Do institutionals and insiders believe in CHE or CRVL?

Does the media favor CHE or CRVL?

Which has higher valuation and earnings, CHE or CRVL?

Summary

How does CorVel compare to Hims & Hers Health?

Is CRVL or HIMS more profitable?

Do analysts prefer CRVL or HIMS?

Which has more volatility & risk, CRVL or HIMS?

Does the media prefer CRVL or HIMS?

Do insiders & institutionals have more ownership in CRVL or HIMS?

Which has stronger earnings and valuation, CRVL or HIMS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRVL vs. The Competition

CorVel Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools